Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study-Reference-Cited by-同舟云学术

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study

Published:2013-04-05 Issue:11 Volume:72 Page:1840-1844
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Fagerli Karen Minde,Lie Elisabeth,van der Heijde Désirée,Heiberg Marte Schrumpf,Kalstad Synøve,Rødevand Erik,Mikkelsen Knut,Lexberg Åse Stavland,Kvien Tore K

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference20 articles.

1. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies;Gossec;Ann Rheum Dis,2012

2. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial;Antoni;Ann Rheum Dis,2005

3. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study;Kavanaugh;Arthritis Rheum,2009

4. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression;Mease;Arthritis Rheum,2004

5. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial;Mease;Arthritis Rheum,2005

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment;Joint Bone Spine;2024-07

2. Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort;2024-03-25

3. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL;RMD Open;2024-02

4. Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review;Rheumatology;2024-01-18

5. Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study;Therapeutic Advances in Musculoskeletal Disease;2024-01